Download - Time-based bioactivity analysis

Transcript

Time-based bioactivity analysis |

Presented By

Date

Time-Based Bioactivity Analysis

Reaxys Medicinal Chemistry

Matthew CLARK

18 May 2016

Time-based bioactivity analysis |

Q: can you analyze activity reported for a target over time, to see the time trend of improvement?

A: Yes

Findings for PIK3 example

• While the most active compound has hovered around the 1-10pM range of affinity, the scaffolds are similar

• Looking over the distribution of activities reported for all PIK3-active compounds, the peak of the distribution has shifted only moderately over time.

Findings for ABL1 example

• Most active compound about 10nM for some time

• Number of highly active compound reports increasing over time

• Trend is moving to more active compounds

Follow Up From Bioactivity Prediction Webinar Question

Time-based bioactivity analysis |

Most Potent Compound Reported for PIK3 Target by Year

(all variants, PIK3* )

The developer of the most-binding compound over time: 2014-16 – Pfizer 2011-13 – GSK (GSK2126458) 2008-10 – Pfizer 2000-07 – Isradipine, Sandoz 1994-96 – Nicarpidine, Syntex

9

10

11

12

13

1994-1996 1997-1999 2000-2002 2003-2005 2006-2007 2008-2010 2011-2013 2014-2016

The scaffolds have some notable similarity over this time period

Time-based bioactivity analysis |

• The peak of reported activities has shifted only moderately

• The number of compounds reported per year increased 1000 fold between 1994 and 2014

5

Distribution of Activities for PIK3 Target Over Time

Graph shows the number of assay reports in each decade of activity for the given time spans That is, how the activities are distributed Note: some compounds are reported in more than one time frame.

0

1000

2000

3000

4000

5000

6000

7000

8000

0 2 4 6 8 10 12

Nu

mb

er o

f C

om

po

un

ds

Rep

ort

ed

-log10[M] activity

1994-1996

1997-1999

2000-2002

2003-2005

2006-2008

2009-2011

2012-2014

2015-2016

Time-based bioactivity analysis |

• 1994-1996 compound is from Plexxicon, most active from Princeton U., most recent from Nektar.

• 2000-2002 leader was Staurosporine!

6

ABL1 Kinase

6

7

8

9

10

11

12

1994-1996 1997-1999 2000-2002 2003-2005 2006-2007 2008-2010 2011-2013 2014-2016

Time-based bioactivity analysis |

• Proportion of highly active compound reports increasing over time

• Total number of compounds reported peaked in 2006-2008

7

ABL1 Kinase Distribution of Activities Over Time

0

500

1000

1500

2000

2500

0 2 4 6 8 10 12

Nu

mb

er o

f C

om

po

un

ds

Rep

ort

ed

-log10[M] activity

1994-1996

1997-1999

2000-2002

2003-2005

2006-2008

2009-2011

2012-2014

2015-2016

Time-based bioactivity analysis |

• Trend shows most active compounds have been small molecules, oligos, and most recently the cyclic peptide cyclohexylgriselimycin

8

DNA Polymerase

6

7

8

9

10

11

12

1994-1996 1997-1999 2000-2002 2003-2005 2006-2007 2008-2010 2011-2013 2014-2016

Time-based bioactivity analysis | 9

DNA Polymerase Distribution of Activities over Time

0

100

200

300

400

500

600

0 2 4 6 8 10 12

Nu

mb

er o

f C

om

po

un

ds

Rep

ort

ed

-log10[M] activity

1994-1996

1997-1999

2000-2002

2003-2005

2006-2008

2009-2011

2012-2014

2015-2016

Trend seems to be for fewer compounds in recent years.